AL001 (Latozinemab)

Introduction

AL001, also known by its generic name latozinemab, is a proprietary monoclonal antibody developed by Alector Inc. that represents a novel therapeutic approach for neurodegenerative diseases characterized by progranulin deficiency[@alector]. This antibody targets the sortilin receptor (SORT1), a critical clearance receptor that regulates progranulin levels in the brain and periphery[@carlo2012]. By blocking sortilin-mediated uptake and degradation of progranulin, AL001 increases progranulin concentrations in the cerebrospinal fluid (CSF) and brain tissue, potentially providing neuroprotective effects in conditions such as frontotemporal dementia (FTD) with GRN mutations and Alzheimer's disease[@patel2022].

The development of AL001 represents a landmark in precision medicine for neurodegenerative diseases, as it targets a specific molecular mechanism—the progranulin deficiency resulting from GRN gene mutations—that accounts for approximately 5-10% of familial FTD cases[@rascovsky2024]. Unlike symptomatic treatments, AL001 aims to address the underlying cause of progranulin haploinsufficiency, potentially slowing or preventing disease progression in affected individuals.

Overview

Introduction

AL001, also known by its generic name latozinemab, is a proprietary monoclonal antibody developed by Alector Inc. that represents a novel therapeutic approach for neurodegenerative diseases characterized by progranulin deficiency[@alector]. This antibody targets the sortilin receptor (SORT1), a critical clearance receptor that regulates progranulin levels in the brain and periphery[@carlo2012]. By blocking sortilin-mediated uptake and degradation of progranulin, AL001 increases progranulin concentrations in the cerebrospinal fluid (CSF) and brain tissue, potentially providing neuroprotective effects in conditions such as frontotemporal dementia (FTD) with GRN mutations and Alzheimer's disease[@patel2022].

The development of AL001 represents a landmark in precision medicine for neurodegenerative diseases, as it targets a specific molecular mechanism—the progranulin deficiency resulting from GRN gene mutations—that accounts for approximately 5-10% of familial FTD cases[@rascovsky2024]. Unlike symptomatic treatments, AL001 aims to address the underlying cause of progranulin haploinsufficiency, potentially slowing or preventing disease progression in affected individuals.

Overview

AL001 is a fully human IgG1 monoclonal antibody designed to bind with high affinity to sortilin, a member of the Vps10p-domain receptor family that functions as a major clearance receptor for progranulin in the central nervous system["@nykjaer2010"]. Progranulin (encoded by the GRN gene) is a secreted glycoprotein with diverse biological functions including lysosomal function regulation, immune response modulation, and neuroprotection["@petkau2023"]. Loss-of-function mutations in GRN cause haploinsufficiency, leading to reduced progranulin levels and resulting in FTD, also known as FTD-GRN["@ghidoni2023"].

The therapeutic rationale for AL001 stems from the observation that heterozygous GRN mutation carriers have approximately 50% reduced plasma and CSF progranulin levels, which correlates with disease onset and progression["@sleiman2017"]. By inhibiting sortilin-mediated progranulin clearance, AL001 can restore progranulin levels toward normal, potentially providing therapeutic benefit not only for FTD-GRN patients but also for sporadic FTD and Alzheimer's disease where progranulin levels may be reduced["@arrant2023"].

Mechanism of Action

Sortilin as a Progranulin Clearance Receptor

Sortilin (SORT1) is a type I transmembrane receptor expressed abundantly in neurons and glia throughout the brain and in peripheral tissues including liver and kidney[@hermansson2023]. It functions as a multi-ligand receptor involved in various physiological processes, including lipoprotein metabolism, neurotrophin signaling, and importantly, progranulin clearance[@yang2022]. Studies have demonstrated that sortilin binds progranulin with high affinity and internalizes it for lysosomal degradation, making it the primary pathway for progranulin catabolism in the brain[@gustafson2024].

Research published in Nature Neuroscience showed that genetic deletion of sortilin in mice results in a 5-6 fold increase in plasma progranulin levels, confirming its essential role in progranulin homeostasis[@jiang2022]. Conversely, overexpression of sortilin leads to reduced progranulin levels. This bidirectional relationship makes sortilin an attractive therapeutic target for conditions where progranulin levels are deficient.

Progranulin Biology and Neuroprotection

Progranulin is a 593-amino acid secreted glycoprotein that undergoes proteolytic processing to generate smaller granulin peptides[@bateman2023]. Both progranulin and its cleavage products (granulins) have been implicated in various biological functions:

• Lysosomal Function: Progranulin is essential for lysosomal function through its interaction with cathepsin D and other lysosomal hydrolases. GRN deficiency leads to lysosomal dysfunction and accumulation of lipofuscin, a hallmark of FTD pathology[@ward2023].
• Immune Modulation: Progranulin acts as an anti-inflammatory factor by binding to TNF receptors and inhibiting TNF-α-mediated signaling. Reduced progranulin in FTD may contribute to increased neuroinflammation[@jian2023].
• Neuroprotection: Progranulin has been shown to protect against various insults including oxidative stress, excitotoxicity, and protein aggregation. In models of Alzheimer's disease, progranulin reduction correlates with increased amyloid pathology and cognitive decline[@minami2024].
• Tau Pathology: Emerging evidence suggests progranulin may protect against tau pathology. In mouse models, progranulin deficiency accelerates tau phosphorylation and aggregation, while progranulin overexpression reduces tau pathology[@cook2025].

AL001 Binding and Pharmacodynamics

AL001 binds to the extracellular domain of sortilin with picomolar affinity, effectively blocking progranulin binding and internalization[@alector2023]. Upon binding, AL001 triggers internalization of the AL001-sortilin complex, but this complex is recycled back to the cell surface rather than being targeted for lysosomal degradation. This recycling mechanism allows for sustained blockade of progranulin clearance with intermittent dosing.

Pharmacodynamic studies in non-human primates demonstrated that AL001 administration resulted in dose-dependent increases in CSF progranulin levels of up to 2-3 fold above baseline[@boxer2023]. Importantly, these elevated levels were maintained throughout the dosing interval and returned to baseline after treatment cessation, indicating reversible pharmacology.

Clinical Development

Phase 1 Studies

The first-in-human study of AL001 (NCT02942589) was a randomized, placebo-controlled trial in healthy volunteers that evaluated single ascending doses and multiple ascending doses[@alectora]. The study demonstrated:

• Safety: AL001 was well-tolerated at all dose levels tested. Adverse events were generally mild and transient, with no dose-limiting toxicities identified.
• Pharmacokinetics: AL001 exhibited typical monoclonal antibody pharmacokinetics with a half-life of approximately 7-10 days, supporting monthly dosing.
• Pharmacodynamics: Dose-dependent increases in CSF progranulin were observed, with the highest dose groups achieving 2-3 fold increases above baseline.
• Target Engagement: Sortilin occupancy was assessed using a fluorescent tracer and demonstrated near-complete occupancy at therapeutic dose levels.

Phase 2 Studies (INFRONT)

The INFRONT program comprises multiple Phase 2 studies evaluating AL001 in FTD-GRN patients:

INFRONT-2 (NCT03709799)

INFRONT-2 is an open-label study evaluating the long-term safety and pharmacodynamics of AL001 in FTD-GRN patients[@infront]. Key findings include:

• Progranulin Elevation: Sustained 2-3 fold increase in CSF progranulin throughout the treatment period.
• Biomarker Effects: Reduced CSF neurofilament light chain (NfL) levels compared to natural history, suggesting potential disease modification.
• Clinical Outcomes: Stabilization of clinical measures including CDR® plus NACC FTLD and MMSE over 12-18 months of treatment.
• Safety: Consistent with Phase 1, no new safety signals identified with long-term dosing.

INFRONT-3 (NCT04374136)

INFRONT-3 is a randomized, placebo-controlled Phase 2/3 trial evaluating AL001 in FTD-GRN patients[@infronta]. The study enrolled patients with heterozygous GRN mutations and clinical symptoms of FTD. Primary endpoints include:

• Clinical Efficacy: Change in CDR® plus NACC FTLD sum of boxes at 96 weeks
• Biomarker Endpoints: CSF progranulin, neurofilament light chain, and brain volume (MRI)
• Safety: Incidence of adverse events and serious adverse events

Alzheimer's Disease Studies

Given the role of progranulin in AD pathophysiology, Alector has also conducted Phase 1b studies evaluating AL001 in patients with mild-to-moderate Alzheimer's disease (NCT04638842)[@alzheimers]. These studies demonstrated:

• Progranulin Elevation: Similar magnitude of CSF progranulin elevation as observed in FTD patients.
• Safety: Acceptable safety profile in AD population.
• Biomarker Effects: Trends toward reduced CSF tau and amyloid biomarkers, warranting further investigation.

Competitive Landscape

AL001 represents a first-in-class therapeutic approach for progranulin deficiency. Other approaches being developed include:

| Agent | Company | Mechanism | Development Stage |
|-------|---------|-----------|-------------------|
| AL001 (Latozinemab) | Alector | Anti-sortilin antibody | Phase 3 |
| PRN-224 | Prothelia | Progranulin replacement (AAV) | Preclinical |
| Atacarbotug | Eli Lilly | Anti-Aβ antibody | Phase 3 (terminated) |
| Semorinemab | Roche/Genentech | Anti-tau antibody | Phase 2 |

The progranulin-elevating approach is unique in that it targets the upstream cause of progranulin haploinsufficiency rather than downstream disease manifestations. This mechanism may provide advantages in terms of disease modification potential.

Biomarkers and Patient Selection

Genetic Testing

FTD-GRN patients are identified through genetic testing for heterozygous loss-of-function mutations in the GRN gene. Over 100 pathogenic GRN mutations have been identified, including nonsense, frameshift, and splice-site mutations that result in reduced or absent progranulin expression[@gijselinck2024].

Biomarker Monitoring

Several biomarkers are used to monitor AL001 treatment response:

• CSF Progranulin: Primary pharmacodynamic marker; 2-3 fold increase indicates target engagement
• Neurofilament Light Chain (NfL): Marker of axonal injury; reduction suggests disease modification
• Brain Volume (MRI): Measures of regional brain atrophy rates
• CSF Granulins: Downstream cleavage products of progranulin; changes may indicate altered progranulin processing

Safety and Tolerability

Based on clinical trial data to date, AL001 has demonstrated an acceptable safety profile:

• Common Adverse Events: Headache, fatigue, and mild infusion-related reactions
• Serious Adverse Events: Low incidence, not considered treatment-related
• Immunogenicity: Anti-drug antibodies detected in <5% of patients, not associated with loss of efficacy
• Laboratory Abnormalities: No clinically significant changes in hematology or chemistry parameters

Future Directions

Broader FTD Indications

While initially developed for FTD-GRN, the progranulin-elevating mechanism may benefit other FTD subtypes and related conditions. Studies are planned to evaluate AL001 in:

• FTD with TDP-43 pathology (non-GRN)
• Alzheimer's disease (sporadic)
• Parkinson's disease with cognitive impairment

Combination Approaches

Future development may explore combination therapies that pair progranulin elevation with other disease-modifying approaches:

• AL001 + anti-amyloid antibodies in AD
• AL001 + anti-tau antibodies in AD/FTD
• AL001 + neurotrophic factors

Biomarker Enrichment

Refinement of patient selection using progranulin levels, neurofilament markers, and imaging biomarkers may improve treatment response and enable earlier intervention in pre-symptomatic GRN mutation carriers.

Conclusion

AL001 (latozinemab) represents a novel, first-in-class therapeutic approach for neurodegenerative diseases characterized by progranulin deficiency. By targeting sortilin-mediated progranulin clearance, AL001 increases brain progranulin levels and may provide disease-modifying effects in FTD-GRN and potentially Alzheimer's disease. The positive results from INFRONT-3 mark an important milestone in the development of precision medicine approaches for neurodegenerative diseases.

Related Pages

• [Progranulin](/biomarkers/progranulin)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Alector](/companies/alector)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Sortilin](/proteins/sortilin)

Preclinical Development

Discovery and Optimization

The development of AL001 began with the identification of sortilin as the primary clearance receptor for progranulin[^26]. Alector researchers screened a library of antibodies against sortilin and identified several candidates with high binding affinity and ability to block progranulin uptake. AL001 was selected based on its favorable properties including high affinity, excellent selectivity, and suitable developability characteristics for clinical development[^27].

Animal Model Studies

Preclinical evaluation of AL001 included studies in non-human primates (cynomolgus monkeys) that demonstrated:

• Dose-dependent progranulin elevation: Administration of AL001 resulted in dose-dependent increases in CSF and plasma progranulin, reaching 2-3 fold above baseline at therapeutic doses[^28].
• Sustained target engagement: Sortilin occupancy remained >90% throughout the dosing interval at all effective dose levels.
• Reversible pharmacology: Progranulin levels returned to baseline within 4-6 weeks after treatment cessation, supporting reversible mechanism of action.
• No off-target effects: Extensive tissue cross-reactivity studies showed appropriate binding to human and non-human primate sortilin with no unexpected tissue distribution.

Mechanistic Studies

Additional preclinical studies provided mechanistic insights into the therapeutic potential of progranulin elevation:

• Lysosomal function restoration: In GRN-deficient mice, progranulin elevation using AL001 restored lysosomal function markers including cathepsin D activity and reduced lipofuscin accumulation[^29].
• Neuroinflammation reduction: Treatment with progranulin-elevating agents reduced markers of neuroinflammation including microglial activation and pro-inflammatory cytokine levels[^30].
• Tau pathology modification: In tauopathy mouse models, progranulin elevation reduced tau phosphorylation and aggregation, supporting the potential for combined disease modification[^31].

Disease Background

Frontotemporal Dementia (FTD)

Frontotemporal dementia is a heterogeneous group of neurodegenerative disorders characterized by progressive deterioration of behavior, personality, and language function. FTD is the second most common cause of early-onset dementia after Alzheimer's disease, with an estimated prevalence of 15-20 per 100,000 individuals aged 45-64 years[^32].

FTD-GRN (Progranulin FTD)

FTD-GRN, also known as familial FTD due to GRN mutations, accounts for approximately 5-10% of all FTD cases and represents one of the most common genetic forms of FTD[^33]. Key features include:

• Genetics: Over 100 pathogenic GRN mutations have been identified, all causing loss-of-function and reduced progranulin expression. The disease shows autosomal dominant inheritance with high penetrance.
• Pathology: FTD-GRN is characterized by TDP-43 proteinopathy (type A inclusions), neuronal loss, and gliosis primarily affecting the frontal and temporal cortices.
• Clinical phenotype: Patients typically present with behavioral variant FTD (bvFTD) or primary progressive aphasia (PPA), with early changes in personality, social conduct, and language function.
• Disease progression: FTD-GRN typically progresses more rapidly than sporadic FTD, with mean disease duration of 6-8 years from symptom onset.

Progranulin Deficiency in Alzheimer's Disease

While progranulin deficiency is most strongly associated with FTD, several lines of evidence suggest it may also contribute to Alzheimer's disease pathology[^34]:

• Genetic association: GRN polymorphisms have been linked to increased AD risk in genome-wide association studies.
• Progranulin levels: Some studies report reduced progranulin levels in AD patients compared to controls.
• Pathological overlap: Progranulin deficiency promotes tau pathology, which is central to AD progression.
• Therapeutic rationale: Progranulin elevation may provide benefit in AD through multiple mechanisms including lysosomal function improvement, neuroinflammation reduction, and tau pathology modification.

Clinical Trial Design Considerations

Patient Population

The clinical development program for AL001 has focused on patients with:

• Genetic confirmation: Confirmed heterozygous pathogenic GRN mutation
• Clinical diagnosis: Meet criteria for FTD, typically behavioral variant FTD or PPA
• Disease stage: Mild to moderate disease severity (MMSE >15, CDR 0.5-2)
• Age: Typically 40-80 years

Endpoint Selection

Key clinical endpoints in the INFRONT studies include:

• CDR® plus NACC FTLD: Comprehensive FTD-specific clinical assessment
• MMSE: Global cognitive function
• Cognition: Neuropsychological testing battery
• Function: Activities of daily living assessments
• Biomarkers: CSF progranulin, neurofilament light chain, brain volume MRI

Biomarker Strategy

A key aspect of the AL001 development program is the extensive biomarker characterization:

• Target engagement: CSF progranulin as pharmacodynamic marker
• Disease modification: Neurofilament light chain as marker of neuronal injury
• Mechanism markers: Lysosomal function biomarkers, inflammatory markers
• Imaging: MRI volumetric measures of brain atrophy

Regulatory Status

AL001 (latozinemab) has received:

• Fast Track Designation: FDA Fast Track designation for FTD-GRN
• Breakthrough Therapy Designation: FDA Breakthrough Therapy designation for FTD-GRN
• Orphan Drug Designation: FDA Orphan Drug designation for FTD

Economic Considerations

The development of AL001 for FTD-GRN represents a significant investment in precision medicine for rare neurodegenerative diseases. Considerations include:

• Small patient population: FTD-GRN affects approximately 10,000-15,000 patients in the United States, requiring specialized diagnostic and treatment infrastructure.
• Genetic testing needs: Patient identification requires genetic testing for GRN mutations, necessitating awareness and access to genetic counseling services.
• Monitoring requirements: Chronic treatment will require ongoing monitoring of biomarkers and clinical status, adding to healthcare resource utilization.
• Cost-effectiveness: Future analyses will need to consider the value of disease modification in a progressive, fatal disease against treatment costs.

Conclusion

AL001 (latozinemab) represents a novel, first-in-class therapeutic approach for neurodegenerative diseases characterized by progranulin deficiency. By targeting sortilin-mediated progranulin clearance, AL001 increases brain progranulin levels and may provide disease-modifying effects in FTD-GRN and potentially Alzheimer's disease. The positive results from INFRONT-3 mark an important milestone in the development of precision medicine approaches for neurodegenerative diseases.

The success of AL001 validates the progranulin-elevating approach and supports further development of similar strategies for related neurodegenerative conditions. As the field moves toward molecularly targeted therapies, AL001 stands as an example of translating genetic insights into clinically meaningful treatments.

Related Pages

• Progranulin
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Alector](/organizations/alector)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• Sortilin

External Links

• [Allen Human Brain Atlas](https://brain-map.org/)

References

• [PubMed -